Stablix
Business Services · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3960 Broadway Fl 6, New York City, New Y...Website
www.stablix.comRevenue
$6.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
2
1
1
1
About Stablix
Founded in 1999, headquartered in New York City, NY, Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need. The company is a creative and multidisciplinary team of scientists, innovators and leaders dedicated to changing the way the company approach drug development by establishing a powerful small-molecule modality for a wide variety of devastating diseases.Explore more
Stablix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Stablix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Stablix launches new products
Earning: See what the market has to say on Stablix recently announced quarterly report
Stablix, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Stablix had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Stablix has new funding data
Congratulate Masked Content for being promoted to Masked Content at Stablix
Check out if Stablix is spiking on competitors!
Check if Stablix has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Stablix as Masked Content
Find 3 more new buyers
Compare Similar Companies to Stablix
Compare insights from companies similar to Stablix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Stablix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Stablix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Stablix.
Stablix Tech Stack
A closer look at the technologies used by Stablix
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Event
Events
Open Position
Executive Move
Board of Directors
Promotion
Executive Move
Stablix News & Media
Stablix Appoints Douglas Williams, Ph.D., to Board of Directors
NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced the appointment of Douglas E. Williams, Ph.D. to its Board of Directors. Dr. Williams is an accomplished biotechnology executive with over 30 years of leadership experience in drug research and development. He is currently President and Chief Executive Officer of Codiak BioSciences.Stablix Appoints Eddine Saiah Chief Scientific Officer and Expands Leadership Team
NEW YORK--(BUSINESS WIRE)--Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced that Eddine Saiah, Ph.D., has joined the company as Chief Scientific Officer. Dr. Saiah is an experienced drug hunter and seasoned leader with over 25 years of experience heading drug discovery, preclinical and early development in large pharmaceutical and small biotech companies. He was most recently CSO at Navitor PharmaceuticalStablix Names Tony Kingsley CEO
NEW YORK--(BUSINESS WIRE)--Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced the appointment of Tony Kingsley as Chief Executive Officer. Mr. Kingsley replaces interim CEO Dr. Carlo Rizzuto, partner at founding investor Versant Ventures, who remains on Stablix’s board of directors. Mr. Kingsley is an experienced biotech CEO with a track record leading and building organizations across multiple scientific dStablix Therapeutics Raises $63M in Series A Funding
Stablix Therapeutics, a New York based biotechnology company which specializes in Targeted Protein Stabilization (TPS), raised $63M in Series A funding. The round was led by Versant Ventures with participation from NEA, Cormorant, Euclidean Capital and Alexandria Real Estate Equities. The company intends to use the funds to build out its platform and advance a […] The post Stablix Therapeutics Raises $63M in Series A Funding appeared first on FinSMEs.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Stablix
Sign Up For FreeTo access detailed company insights
Founded in 1999, headquartered in New York City, NY, Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need. The company is a creative and multidisciplinary team of scientists, innovators and leaders dedicated to changing the way the company approach... Read More
